The study was supported by grants from the National Institute on Aging, part of the National Institutes of Health longitudinal Study of the transition from healthy aging, Alzheimer’s disease, ‘David K. Johnson, Martha Storandt, John C. James. E. Arch Neurol, October 2009, 66: 1254 bis 1259th.
The authors wrote that more and more researchers are looking at now, if healthy aging is transformed into the early stages of dementia. – As new interventions are available, it is the disease as early the disease as early as possible, they said.
The study was the work of Dr. David K. Johnson of the University of Kansas, Lawrence, and colleagues, the October issue the October issue of the Archives of Neurology, one of the JAMA / Archives journals.About the clinical trialsdose-finding study:In a double – blind, placebo – controlled study, 458 OCD patients have either Cipralex or 40mg of paroxetine or placebo. The study duration was 24 weeks with an primary efficacy evaluation after 12 weeks of .
H. Lundbeck A to treat of OCDH. Lundbeck A / S would be approval Cipralex in Europe known for treatment of OCD .
– the primary efficacy analyzing showed a statistically significantly superior activity of Cipralex compared with placebo on the time to recurrence of Shoulders, with a 52 percent recurrence rates into the placebo group compared to an 23 percent – installment in the Cipralex group2.
– That risk of relapse 2 stood, controlled trial times higher in the in the placebo group compared to patients with Cipralex 2..